News and Document archive source
copyrighted material disclaimer at bottom of page

NewsMinecabal-elitecorporatepharmaceutical — Viewing Item


New york state sues paxil company over coverup { June 3 2004 }

Original Source Link: (May no longer be active)
   http://www.nytimes.com/2004/06/03/business/03GLAX.html

http://www.nytimes.com/2004/06/03/business/03GLAX.html
http://www.dfw.com/mld/dfw/news/nation/8827035.htm?1c

June 3, 2004
New York State Official Sues Drug Maker Over Test Data
By GARDINER HARRIS

In a novel claim testing the way that the $400 billion worldwide pharmaceutical industry is regulated, the New York State attorney general, Eliot Spitzer, sued the British-based drug giant GlaxoSmithKline yesterday, accusing the company of fraud in concealing negative information about its popular antidepressant medicine Paxil.

The civil lawsuit, filed in State Supreme Court in Manhattan, contends that GlaxoSmithKline engaged in persistent fraud by failing to tell doctors that some studies of Paxil showed that the drug did not work in adolescents and might even lead to suicidal thoughts. Far from warning doctors, the suit contends, the company encouraged them to prescribe the drug for youngsters.

"The point of the lawsuit is to ensure that there is complete information to doctors for making decisions in prescribing," Mr. Spitzer said in an interview. "The record with Paxil, we believe, is a powerful one that shows that GSK was making selective disclosures and was not giving doctors the entirety of the evidence."

GlaxoSmithKline officials issued a statement yesterday saying in part that the company "has acted responsibly in conducting clinical studies in pediatric patients and disseminating data from those studies."

On Wall Street yesterday, the American depository receipts of GlaxoSmithKline fell $1.38, or 3.2 percent, to $41.39.

Mr. Spitzer filed his suit at a time that the tendency of many drug companies to publicize only studies with positive results has come under increasing criticism.

As he has done in actions involving the financial services and mutual fund industries, Mr. Spitzer is entering regulatory terrain that has been largely the preserve of the federal government, in this case the Food and Drug Administration. This time, though, he maintains that his suit is not a criticism of federal drug regulators.

"This isn't Harvey Pitt and the S.E.C.," he said, referring to the former chief of the Securities and Exchange Commission, whom Mr. Spitzer criticized as less than vigorous in enforcing federal securities laws. Instead, Mr. Spitzer said that the F.D.A. had been hamstrung by court rulings that have used free-speech arguments to limit the agency's power to regulate what drug companies can say to doctors. Such rulings do not limit his powers, Mr. Spitzer said.

"You cannot invoke free-speech arguments as a defense to fraud," he added.

Similar suits against other drug companies are likely, Mr. Spitzer said. "This is an area that we're interested in," he said, "and I think there are other cases out there that are analogous."

A spokeswoman for the F.D.A. would not comment on the lawsuit but noted that the agency required companies to submit all data related to the safety of their drugs. Because so much drug company data submitted is considered proprietary, it is up to the F.D.A. to decide when to disclose possible public safety concerns.

That is what it did last year, when it warned doctors on the use of Paxil for adolescents and children. Earlier this year, it required antidepressant makers to strengthen suicide warnings on labels.

British drug regulators have banned the use of all but Prozac for the treatment of depression in adolescents and children. Prozac, made by Eli Lilly & Company, received a major American endorsement this week when the widely anticipated results of a study sponsored by the National Institute of Mental Health indicated that Prozac was superior to talk therapy alone or a placebo in treating depression among teenagers. The study did not address suicide risks.

Civil suits have been filed against Glaxo and some other makers of antidepressants by patients or surviving relatives, contending that the drugs caused violent or suicidal behavior. Some criminal defendants have contended that violent acts were a result of using the drugs.

Mr. Spitzer's lawsuit is part of a broad assault by prosecutors on the drug industry's marketing practices. Last month, for example, federal prosecutors in Boston announced a settlement with the world's largest drug maker, Pfizer; the company agreed to pay $430 million and to plead guilty to charges that its Warner-Lambert unit promoted the drug Neurontin to doctors for the treatment of conditions where no benefit had been proved.

TAP Pharmaceuticals agreed to pay $800 million for inappropriate marketing practices, and its former executives are facing federal criminal charges in Boston. Schering-Plough has acknowledged in regulatory filings that it is likely to be indicted for improper marketing practices. Other companies are being investigated.

At issue in most of these investigations, including Mr. Spitzer's Paxil suit, is the marketing of approved drugs for off-label uses those not specifically approved by the F.D.A. While doctors are free to prescribe an approved drug for any use, the manufacturers are supposed to limit their marketing to those uses with F.D.A. clearance.

The new wrinkle in Mr. Spitzer's suit is his argument that a drug maker is committing fraud if it does not tell doctors about trials of a medication that raise safety concerns.

"I'm certainly not the person to determine whether Paxil is appropriate or not for any given patient," Mr. Spitzer acknowledged. "But what I can do is ensure the information to doctors is fair and complete so that those equipped to make this determination can do so."

Dr. Barry Perlman, president of the New York State Psychiatric Association, said in an interview that his organization supported a crackdown on the failure to disclose negative information on drugs.

"Whenever we don't have the complete picture," he said, "we can't prescribe ethically and appropriately, and that's an enormous obstacle to good care."

Richard Merrill, a University of Virginia law professor and a former general counsel at the F.D.A, compared Mr. Spitzer's suit to product-liability lawsuits by individuals. He said the suit was the first by a public official against the drug industry.

Pharmaceutical companies sponsor most clinical trials of drugs and, in many cases, they jealously guard the data that results. If a test suggests that a drug is effective in treating a certain condition, the company will push to get its results published in a prestigious journal. If the results reflect poorly on the drug, they often never appear in public.

Experts have long criticized the tendency in the industry to publish only positive clinical trials, arguing that this distorts medical practice and undermines the scientific process. Some have suggested that the results of all clinical trials should be published in a federal registry.

But some say that doctors are unlikely to consult such a registry and will continue to be influenced by trial results published in leading journals.

Mr. Spitzer's suit is the first to suggest a way of resolving such matters. If a company's marketing message is at odds with the results of its own, suppressed clinical trial, he argues, the company is liable for damages under consumer fraud laws.

In the case of Paxil, GlaxoSmithKline sponsored five trials of the drug in adolescents suffering from major depression. The company undertook the trials to qualify for a six-month extension of Paxil's patent granted under a federal law that encourages the testing of drugs in children. But it published only one of the trials, which showed mixed effect. The unpublished trials failed to show any benefit for the drug and suggested that it might increase the risk of suicide.

An internal memo cited in the suit said the company should have "effectively managed the dissemination of these data in order to minimize any potential negative commercial impact."

And, according to the suit, the company told its sales representatives that "Paxil demonstrates remarkable efficacy and safety in the treatment of adolescent depression." The suit contends that sales representatives passed this on to doctors.

The company's statement yesterday said the memo, written in 1998 before the merger of SmithKline Beecham and Glaxo Wellcome of Britain that created the current company "is inconsistent with the facts and does not reflect the company position."



Copyright 2004 The New York Times Company


40 percent of americans take prescription drugs
ADD drugs give hallucinations of bugs and snakes { March 22 2006 }
American painkiller use skyrocketing
Anti depresents linked to suicide
Antibiotic causes liver damage
Antidepressant use by adults surges { December 3 2004 }
Antidepressants addictive to some people { August 6 2006 }
Antidepressants remove obsessive focus of love
Antidepressiants increases chance of suicide { December 13 2006 }
Arthritis drugs causing cancer in childen { April 29 2008 }
Bayer sent riskier drug asia latinamerica { May 22 2003 }
Birth defects from paxil in pregnant women { December 8 2005 }
Canada makes drug deals with 2 states against fda wishes { October 5 2004 }
Cholesterol drug causes kidney damage contradicting fda { May 24 2005 }
Cholesterol meds lower test results not improving health { January 15 2008 }
Clinical trials biased by profit funding
Company hid heartattack data for painkiller { December 8 2005 }
Congressman moves retired to drug lobby
Dc council legislation blocks pharmaceutical price gounging { September 21 2005 }
Doctor gives anti depressants to 4 yr old girl
Doctors get kickbacks to promote drugs
Doctors prescribe paxil whenever asked { April 27 2005 }
Drug aleve increases stroke heart attack risk { December 21 2004 }
Drug bill well financed victory
Drug company criminal charges { May 31 2003 }
Drug firms hide studies showing suicidal behavior { September 10 2004 }
Drug firms hype up diseases to boost sales
Drug leader at NIH takes pharmaceutical money { December 22 2004 }
Fda accused too cozy with pharmaceuticals { November 18 2004 }
Fda approval surprises many doctors
Fda prevented drug expert from speaking on anti depressants { April 16 2004 }
Fda wants suicide warning on anti depressants { March 23 2004 }
Fda whistle blower seeks legal help { November 24 2004 }
Fraud studies made by drug company { March 2008 }
Man arrested if not medicating child with drugs { June 7 2004 }
Mccain knocks steroids baseball
Minnesota school shooter using prozac and others { March 26 2005 }
More anti depressant drug warnings by fda
New diabetes pill poses deadly risk
New york state sues paxil company over coverup { June 3 2004 }
Newer antipsychotic drugs more costly less effective { September 20 2005 }
Parents reverse child hyper activity without drugs { December 22 2006 }
Paxil link found with birth defects
Pharmaceutical cholesterol drugs not lowering risk
Pharmaceutical companies court doctors for sells { April 11 2008 }
Pharmaceutical companies using tax exempt charities { June 28 2006 }
Pharmaceutical secrecy on antidepressant data { January 29 2004 }
Pharmaceuticals in tap water through sewage { March 10 2008 }
Pharmaceuticals pay fda more for speedy approvals { November 22 2006 }
Return of vioxx unusual not unprecendented
Rise of european behavior controlling drug
Ritalin could be dangerous to heart { February 10 2006 }
Senators told fda too cozy with drug industry { November 18 2004 }
Sharp rise in ritalin { July 19 2003 }
Sleeping pill causes sleep driving { March 15 2007 }
Sleeping pills once a day increase death rate { March 23 2006 }
Statin drug takers suffer heart attacks anyway
Study criticizes painkiller marketing { January 25 2005 }
Study drugs for students growing { June 11 2006 }
Study shows no good effect from anti depressants { February 25 2008 }
Suicide risk increase with antidepressants { February 18 2005 }
Supreme court allows pharmaceutical to bulldoze homes { June 23 2005 }
Teens increasing pharmaceutical drug abuse { April 21 2005 }
Teens use pharmaceutical drugs to get high { December 21 2006 }
Unapproved drug tested on children in nigeria { May 7 2006 }
Unfavorable drug studies never reported
Viox risk seen with short term use { May 17 2006 }
Women participating in lilly drug trial hangs self { February 9 2004 }

Files Listed: 68



Correction/submissions

CIA FOIA Archive

National Security
Archives
Support one-state solution for Israel and Palestine Tea Party bumper stickers JFK for Dummies, The Assassination made simple